Advances in the Management of Pancreatic Cancer

  • M. Tempero
Conference paper
Part of the Progress in Anti-Cancer Chemotherapy book series (ANTI-CANCER, volume 3)


Adenocarcinoma of the exocrine pancreas remains a profound therapeutic challenge. Incremental improvements in overall survival have been small and the current 5 year survival of patients with pancreatic cancer is only 4% [1]. In the United States, this disease is a the fourth leading cause of cancer death in men and the fifth cause of cancer death in women.


Pancreatic Cancer Pancreatic Carcinoma Pancreatic Adenocarcinoma Cyproterone Acetate Tumor Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Landis SH, Murray T, Bolden S, Bolden S, Wingo PA (1998) Cancer Statistics CA Can J Clinicians 48:6–29CrossRefGoogle Scholar
  2. 2.
    Warshaw AL, Fernandez-del C (1992) Pancreatic caminoma. N Engl J Med 326:455–465PubMedCrossRefGoogle Scholar
  3. 3.
    Crist DW, Cameron JL (1994) The current status of the Whipple operation for periampullary carcinoma. Adv Surg 25:21–49Google Scholar
  4. 4.
    Trede M, Schwall G, Saeger HD (1990) Survival after pancreatoduodenectomy. Ann Surg 211:447–58PubMedCrossRefGoogle Scholar
  5. 5.
    Kaiser MH, Ellenberg SS (1985) Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903CrossRefGoogle Scholar
  6. 6.
    Gastrointestinal Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006–2010CrossRefGoogle Scholar
  7. 7.
    ECC09 (1997) The European Cancer Conference (Hamburg, 14–18 September) Abstracts, Eur J Cancer 33(Suppl 8): 1–380Google Scholar
  8. 8.
    Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, Buttmann MC, Litwin S, Salazar H, Eisenberg BL (1995) A pilot study of preoperative chemoradi- ation for patients with localized adenocarcinoma of the pancreas. Am J Surg 169:71–77PubMedCrossRefGoogle Scholar
  9. 9.
    Evans EB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Chamsangavej C, Fenogllo CH, Amers FC (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335–1339PubMedCrossRefGoogle Scholar
  10. 10.
    Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goxwitz MS, Rich TA, Evans DB (1997) Preoperative and postoperative chemoradiation strategies in patients with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928–937PubMedGoogle Scholar
  11. 11.
    Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kaiser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48:1705–1710PubMedCrossRefGoogle Scholar
  12. 12.
    Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80:751–755CrossRefGoogle Scholar
  13. 13.
    Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H (1997) Protracted 5-Fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79:1516–1520PubMedCrossRefGoogle Scholar
  14. 14.
    Robertson JM, Ensminger WD, Walker S, Lawrence TS (1997) A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 37:331–335PubMedCrossRefGoogle Scholar
  15. 15.
    Safran H, King TP, Choy H, Hesketh PH, Wolfe B, Altenhein E, Sikov W, Rosmarin A, Akerly W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ (1997) Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study. J Clin Oncol 153:901–907Google Scholar
  16. 16.
    Boz G, DePaoli A, Roncadin M, Franchin G, Galligioni E, Arcicasa M, Bortolus R, Gobitti C, Minatel E, Innocente R et al (1991) Radiation therapy combined with chemotherapy for inoperable pancreatic carcinoma. Tumori 77:61–64PubMedGoogle Scholar
  17. 17.
    Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensiti- zation of pancreatic cancer cells by 2’, 2’-difluoro-2’-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867–872PubMedCrossRefGoogle Scholar
  18. 18.
    Roldan GE, Gunderson LL, Nagomey DM, Martin JK, Ilstmp DM, Holbrook MA, Kvols LK, Mcllrath DC (1988) External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61:1110–1116PubMedCrossRefGoogle Scholar
  19. 19.
    Tempero M (1998) Chemotherapy of Pancreatic Cancer. In: Reber H(ed) Pancreatic Cancer: Pathogenesis, Diagnosis, and Treatment Humana Press, Totowa, NJ pp 265- 280Google Scholar
  20. 20.
    Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo JH (1996) A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78:627–632PubMedGoogle Scholar
  21. 21.
    Ahlgren JD (1996) Chemotherapy for pancreatic carcinoma. Cancer 78:654–663PubMedGoogle Scholar
  22. 22.
    Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2,2’-difluorodeoxycy- tidine) in patients with adenocarcinoma of the pancreas. Invest New Crugs 12:29–34CrossRefGoogle Scholar
  23. 23.
    Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Gripps MC, Portenoy RK, Stomiolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  24. 24.
    Wong A, Chan A, Arthur K (1987) Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 71:749–750PubMedGoogle Scholar
  25. 25.
    Keating JJ, Johnson PJ, Cochrane AMG, Gazzard BG, Krasner N, Smith PM, Trewby PN, Wheeler P, Wilkinson SP, Williams R (1989) A prospective randomised trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 60:789–792PubMedCrossRefGoogle Scholar
  26. 26.
    Allegretti A, Lionetto R, Saccomanno S, Paganuzzi M, Onetto M, Martinoli C, Rollandi G, Marugo M, Fazzuoli L, Pugliese V (1993) LH-RH analogue treatment in adenocarcinoma of the pancreas: A phase II study. Oncology 50:77–80PubMedCrossRefGoogle Scholar
  27. 27.
    Philip PA, Carmichael J, Tonkin K, Buamah PK, Britton J, Dowsett M, Harris AL (1993) Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 67:379–382PubMedCrossRefGoogle Scholar
  28. 28.
    DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG (1991) Fluorouracil and high-dose leu- coverin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 9:2128–2133PubMedGoogle Scholar
  29. 29.
    Scheithauer W, Pfeffel F, Komek G, Marczell A, Wiltschke C, Funovics J (1992) A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 70:1864–1866PubMedCrossRefGoogle Scholar
  30. 30.
    Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B (1992) Phase II evaluation of fluorouracil and recombinant ot- 2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70:2073–2076PubMedCrossRefGoogle Scholar
  31. 31.
    Smith FP, Hoth DF, Levin B, Karlin DA, Macdonald JS, Woolley PV, Schien PS (1980) 5-fluorouracil, adriamycin and mitomycin-C(FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014–2018PubMedCrossRefGoogle Scholar
  32. 32.
    Bukowski RM, Schacter LP, Groppe CW, Hewlett JS, Weick JK, Livingston RB (1982) Phase II trial of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 50:197–200PubMedCrossRefGoogle Scholar
  33. 33.
    Gastrointenstinal Tumor Study Group (1986) Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomoycin C plus fluorouracil. J Clin Oncol 4:1794–1798Google Scholar
  34. 34.
    Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R (1991) A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine and arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68:965–969PubMedCrossRefGoogle Scholar
  35. 35.
    Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifie DM, Barlow JF (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253:2061–2067PubMedCrossRefGoogle Scholar
  36. 36.
    Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard CF (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. BR J Surg 81:882–885PubMedCrossRefGoogle Scholar
  37. 37.
    Glimelius B, Hoffman K, Sjöden PO, Jacobsson G, Sellström H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600PubMedCrossRefGoogle Scholar
  38. 38.
    Mallinson CN, Rake MO, Cocking JD (1980) Chemotherapy in pancreatic cancer. Br Med J 281:1589–1591PubMedCrossRefGoogle Scholar
  39. 39.
    Plunkett W, Huang P, Searcy CE et al (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 10:3–15Google Scholar
  40. 40.
    Brand R, Capadano M, Tempero M (1997) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15:331–341PubMedCrossRefGoogle Scholar
  41. 41.
    Kawai Y, Yang LY, Plunkett W (1998) Inhibition of repair of cisplatin-induced DNA damage in human colon carcinoma cells by gemcitabine. AACR Proc 39:156, Abst #1068Google Scholar
  42. 42.
    Ura H, Obara T, Shudo R, Itoh A, Tanno S, Fujii T, Nishino N, Kohgo Y (1998) Selective cytotoxicity of famesylamine to pancreatic carcinoma cells and Ki-ras-trans- formed fibroblasts. Mol Carcinog 21:93–99CrossRefGoogle Scholar
  43. 43.
    Moasser MM, Sepp-Lorenziono L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N (1998) Famesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sei USA 95:1369–1374CrossRefGoogle Scholar
  44. 44.
    Aoli K, Yoshida T, Sugimura T et al (1995) Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55:3810–3816Google Scholar
  45. 45.
    Cai DW, Mukhopadhyay T, Roth JA (1995) Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 2:199–205PubMedGoogle Scholar
  46. 46.
    Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373–376PubMedCrossRefGoogle Scholar
  47. 47.
    MacLean GD, Reddish MA, Koganty RR, Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic Stn vaccine. J Immunother Emphasis Tumor Immunol 19:59–68PubMedCrossRefGoogle Scholar
  48. 48.
    Jaffee EM, Pardoll DM (1997) Considerations for the clinical development of cytokine gene-transducted tumor cell vaccines. Methods 12:143–153PubMedCrossRefGoogle Scholar
  49. 49.
    Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD (1990) Phase II trial of interferon gamma and monoclonal antibody 17–1A in pancreatic cancer: Biologic and clinical effects. J Clin Oncol 12:2019–2026Google Scholar
  50. 50.
    Reithmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, and the German Cancer Aid 17–1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’C colorectal carcinoma. Lancet 343:1177–1183CrossRefGoogle Scholar
  51. 51.
    Tempero MA, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Wise-carver J, Colcher D (1997) High dose therapy with labeled monoclonal antibody CC49: A phase I trial. J Clin Oncol 15:1518–1528PubMedGoogle Scholar
  52. 52.
    Leichner PK, Akabani G, Colcher D, Harrison K, Hawkins W, Eckblade M, Bara-nowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero M (1997) Patient-specific dosimetry of indium-III-and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 38:512–516PubMedGoogle Scholar
  53. 53.
    Breitz HB, Weiden PL, Vanderheyden JL et al (1992) Clinical experience with Rhenium 186 labeled monoclonal antibodies for radioimmunotherapy: Results of Phase 1 trials. J Nucl Med 33:1099–1109PubMedGoogle Scholar
  54. 54.
    Bramhall S (1997) The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatology 2:1–12Google Scholar

Copyright information

© Springer-Verlag France 1999

Authors and Affiliations

  • M. Tempero

There are no affiliations available

Personalised recommendations